文献速递淋巴瘤造血干细胞移植与细胞治疗

有效的桥接治疗可改善大B细胞淋巴瘤患者CD19 CAR-T结局并维持安全性

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

该研究评估375例接受阿基仑赛或替沙仑赛治疗的大B细胞淋巴瘤患者的桥接治疗模式与反应对CD19 CAR-T结局的影响。桥接治疗安全,对桥接治疗达完全或部分缓解与疾病进展和死亡风险降低42%相关。多因素分析显示对末线治疗反应、无大肿块及含泊洛妥珠单抗方案与桥接治疗反应可能性相关。

要点

  • 桥接治疗对患者安全,发病率或死亡率极低。
  • 对桥接治疗达完全或部分缓解与CD19 CAR-T后疾病进展和死亡风险降低42%相关。
  • 对末线治疗反应、无大肿块及含泊洛妥珠单抗方案与桥接治疗反应可能性相关。

核心结论

  • 大B细胞淋巴瘤的桥接治疗应仔细规划以达到最佳反应和减瘤,从而改善CD19 CAR-T相关患者结局。
  • 含泊洛妥珠单抗方案应强烈考虑用于所有合适患者。
  • 替沙仑赛给药前桥接治疗未达完全或部分缓解时,如有可能可考虑进一步桥接治疗。

研究设计与样本

  • 评估375例接受阿基仑赛或替沙仑赛治疗的成人大B细胞淋巴瘤患者的桥接治疗模式与反应及其与CD19 CAR-T后结局的关系。

主要发现

  • 多数患者接受化疗桥接治疗(57%)或放疗桥接治疗(17%)。
  • 桥接治疗对患者安全,发病率或死亡率极低。
  • 对桥接治疗达完全或部分缓解使CD19 CAR-T治疗后疾病进展和死亡风险降低42%。
  • 多因素分析识别出与桥接治疗反应可能性相关的因素,包括对末线治疗的反应、无大肿块及使用含泊洛妥珠单抗的化疗方案。
  • 数据提示对桥接治疗达完全或部分缓解对替沙仑赛可能比对阿基仑赛更重要,因为所有接受替沙仑赛且对桥接治疗未达部分缓解的患者在CD19 CAR-T输注后12个月内均出现明显复发。

临床怎么用

  • 大B细胞淋巴瘤的桥接治疗应仔细规划以达到最佳反应和减瘤,以改善CD19 CAR-T相关患者结局。
  • 含泊洛妥珠单抗方案应强烈考虑用于所有合适患者。
  • 替沙仑赛给药前桥接治疗未达完全或部分缓解时,如有可能可考虑进一步桥接治疗。
  • 当前实践由医生偏好而非既定证据指导。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell (CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterized. Current practice is guided through physician preference rather than established evidence. Identification of effective BT modalities and factors predictive of response could improve both CAR-T intention to treat and clinical outcomes. We assessed BT modality and response in 375 adult patients with LBCL in relation to outcomes after axicabtagene ciloleucel (Axi-cel) or tisagenlecleucel (Tisa-cel) administration. The majority of patients received BT with chemotherapy (57%) or radiotherapy (17%). We observed that BT was safe for patients, with minimal morbidity or mortality. We showed that complete or partial response to BT conferred a 42% reduction in disease progression and death after CD19CAR-T therapy. Multivariate analysis identified several factors associated with likelihood of response to BT, including response to last line therapy, the absence of bulky disease, and the use of polatuzumab-containing chemotherapy regimens. Our data suggested that complete or partial response to BT may be more important for Tisa-cel than for Axi-cel, because all patients receiving Tisa-cel with less than partial response to BT experienced frank relapse within 12 months of CD19CAR-T infusion. In summary, BT in LBCL should be carefully planned toward optimal response and disease debulking, to improve patient outcomes associated with CD19CAR-T. Polatuzumab-containing regimens should be strongly considered for all suitable patients, and failure to achieve complete or partial response to BT before Tisa-cel administration may prompt consideration of further lines of BT where possible.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Roddie C, Neill L, Osborne W, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023. PMID: 36724512. doi:10.1182/bloodadvances.2022009019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。